Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NVST
NVST logo

NVST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
23.935
Open
23.640
VWAP
23.64
Vol
4.53M
Mkt Cap
3.83B
Low
23.440
Amount
106.97M
EV/EBITDA(TTM)
10.99
Total Shares
162.73M
EV
4.21B
EV/OCF(TTM)
15.47
P/S(TTM)
1.41
Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.
Show More

Events Timeline

(ET)
2026-05-06
20:00:00
Strong Earnings in Tech Push S&P 500 to Record Highs
select
2026-05-06
17:00:00
Company Reports Q1 Revenue of $706M, Exceeds Expectations
select
2026-05-06
17:00:00
Company Confirms FY26 Core Sales Growth 2%-4%
select
2026-05-04 (ET)
2026-05-04
17:10:00
Cooper Companies Appoints Paul Keel as Independent Director
select

News

Newsfilter
5.0
05-22Newsfilter
Henry Schein Appoints New Board Chairman
  • New Board Chairman: Henry Schein announced that William K. 'Dan' Daniel will become the Independent Chairman of the Board effective May 21, 2026, succeeding Stanley M. Bergman, who served 44 years and is now Chairman Emeritus, recognizing his extraordinary contributions to the company.
  • Rich Leadership Experience: Daniel joined the Henry Schein Board in May 2025 and brings decades of board and global executive leadership experience in healthcare and industrial sectors, having served 14 years as Executive Vice President at Danaher Corporation, overseeing multiple business segments including the dental portfolio.
  • Strategic Continuity and Growth: Daniel expressed his commitment to building upon the foundation laid by Bergman, emphasizing the latter's strategic leadership and dedication to Henry Schein's mission, which has shaped the company into a leading industry provider, and he looks forward to supporting this legacy.
  • Growth Outlook: CEO Fred Lowery expressed gratitude for Bergman's contributions and highlighted that Daniel's deep understanding of the business and distinguished track record will be instrumental in executing the company's long-term strategy, enhancing the quality and accessibility of healthcare services.
Yahoo Finance
9.5
05-16Yahoo Finance
Envista Reports Strong Q1 Sales Growth Amid Challenges
  • Strong Sales Performance: Envista's Q1 revenue reached $705.5 million, exceeding analyst expectations of $675.2 million by 14.4%, indicating robust growth driven by orthodontics, diagnostics, and consumables.
  • Improved Profitability: Adjusted EPS was $0.36, beating the $0.31 estimate by 14.9%, while adjusted EBITDA stood at $98.9 million with a 14% margin, showcasing effective cost control measures.
  • Cautious Market Reaction: Despite surpassing expectations, the market reacted negatively due to investor concerns over macroeconomic uncertainties and tariff impacts, with CEO Paul Keel acknowledging these as ongoing challenges.
  • Future Outlook: Management reiterated full-year adjusted EPS guidance of $1.40, with expectations that China's Value-Based Procurement (VBP) will commence in Q2 or Q3, emphasizing the need to monitor market developments closely for revenue impacts.
seekingalpha
9.5
05-07seekingalpha
Envista Holdings Reports Strong Q1 2026 Earnings with 9.5% Core Growth
  • Core Growth Performance: Envista achieved a 9.5% core growth in Q1 2026, with ortho consumables and diagnostics showing double-digit increases, despite weaker performance in China, indicating strong global demand and competitive positioning.
  • Acquisition and Integration: The completion of the acquisition of Versah enhances Envista's implants platform, expected to boost growth, margins, and EPS, thereby solidifying its leadership in the medical device sector.
  • Stock Buyback Program Expansion: The board authorized an additional $300 million for stock repurchases, reflecting management's confidence in future performance and a proactive strategy to enhance shareholder value through capital returns.
  • Financial Outlook and Risks: Envista reaffirmed its 2026 guidance of 2% to 4% core growth, while acknowledging geopolitical and macroeconomic uncertainties, yet remains optimistic about future cash flow and profitability.
seekingalpha
9.5
05-06seekingalpha
Envista Releases 2026 Financial Outlook with Strong Q1 Results
  • Q1 Performance Exceeds Expectations: Envista reported a Q1 non-GAAP EPS of $0.36, beating estimates by $0.05, indicating strong market performance that is likely to positively impact stock prices.
  • Significant Revenue Growth: The company achieved Q1 revenue of $706 million, a 14.4% year-over-year increase, surpassing market expectations by $25.93 million, reflecting successful sales and market expansion efforts that bolster investor confidence.
  • 2026 Financial Guidance: Envista maintains its 2026 core sales growth outlook at 2% to 4%, with adjusted EBITDA growth projected at 7% to 13%, demonstrating the company's confidence and stability in future growth prospects.
  • Clear EPS Targets: The company anticipates adjusted diluted EPS for 2026 to be between $1.35 and $1.45, alongside nearly 100% free cash conversion, showcasing strong financial health and sustainable profitability.
Yahoo Finance
6.0
04-15Yahoo Finance
Envista Holdings Receives Overweight Rating
  • Rating Upgrade: Envista Holdings (NVST) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor interest.
  • Price Target Set: The average price target set by analysts is $28.50, suggesting potential upside for the company's stock price, which could drive short-term price increases.
  • Increased Market Confidence: An overweight rating typically signifies that analysts believe the company will outperform its peers in the industry, potentially enhancing investor confidence in the company's long-term growth prospects.
  • Heightened Investor Attention: With the rating upgrade, Envista Holdings may attract more institutional investor interest, thereby increasing its market liquidity and stock price stability.
NASDAQ.COM
6.5
03-16NASDAQ.COM
Three Strong Value Stocks to Consider
  • OptimizeRx Earnings Growth: OptimizeRx Corporation (OPRX) holds a Zacks Rank #1, with the consensus estimate for its current year earnings rising by 12.6% over the past 60 days, indicating strong growth potential in the digital healthcare technology sector.
  • Envista Profit Increase: Envista Holdings Corporation (NVST) also carries a Zacks Rank #1, and its current year earnings estimate has increased by 11.9% in the last 60 days, reflecting its sustained competitiveness in the dental products market.
  • Strattec Security Growth: Strattec Security Corporation (STRT) maintains a Zacks Rank #1, with next year's earnings expected to grow by 19.3%, showcasing a robust development trend in the automotive technology sector.
  • Significant Valuation Advantage: All three companies exhibit low price-to-earnings ratios, with OptimizeRx at 6.53, Envista at 17.50, and Strattec at 11.84, all below their respective industry averages, highlighting their strong investment value.
Wall Street analysts forecast NVST stock price to rise
13 Analyst Rating
Wall Street analysts forecast NVST stock price to rise
5 Buy
7 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
18.00
Averages
22.22
High
27.00
Current: 0.000
sliders
Low
18.00
Averages
22.22
High
27.00
Baird
Jeff Johnson
Outperform
maintain
$30 -> $31
AI Analysis
2026-05-07
Reason
Baird
Jeff Johnson
Price Target
$30 -> $31
AI Analysis
2026-05-07
maintain
Outperform
Reason
Baird analyst Jeff Johnson raised the firm's price target on Envista to $31 from $30 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and another quarter of solid execution.
JPMorgan
Neutral
maintain
$26 -> $29
2026-05-07
Reason
JPMorgan
Price Target
$26 -> $29
2026-05-07
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Envista to $29 from $26 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NVST
Unlock Now

Valuation Metrics

The current forward P/E ratio for Envista Holdings Corp (NVST.N) is 20.33, compared to its 5-year average forward P/E of 20.04. For a more detailed relative valuation and DCF analysis to assess Envista Holdings Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
20.04
Current PE
20.33
Overvalued PE
24.00
Undervalued PE
16.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
12.58
Current EV/EBITDA
10.87
Overvalued EV/EBITDA
14.64
Undervalued EV/EBITDA
10.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.83
Current PS
1.30
Overvalued PS
2.39
Undervalued PS
1.26

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Stocks for short term gans
Intellectia · 19 candidates
Market Cap: >= 2.00BRsi Category: moderate, overboughtRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
LBTYB logo
LBTYB
Liberty Global Ltd
6.07B
PAHC logo
PAHC
Phibro Animal Health Corp
2.15B
ALGT logo
ALGT
Allegiant Travel Co
2.10B
NVST logo
NVST
Envista Holdings Corp
4.77B
XPO logo
XPO
XPO Inc
23.85B
RRX logo
RRX
Regal Rexnord Corp
14.06B
day trade most profitable right now
Intellectia · 24 candidates
Market Cap: >= 500.00MRegion: USPrice: $5.00 - $150.00Volume: >= 2,000,000Price Change Pct: >= $4.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PLSE logo
PLSE
Pulse Biosciences Inc
1.33B
LBTYB logo
LBTYB
Liberty Global Ltd
6.26B
BILL logo
BILL
BILL Holdings Inc
4.32B
STKL logo
STKL
Sunopta Inc
756.00M
LUMN logo
LUMN
Lumen Technologies Inc
7.85B
MSTR logo
MSTR
Strategy Inc
40.50B
what trades can I do within my budget
Intellectia · 43 candidates
Region: USPrice: $5.00 - $50.00Rsi Category: moderate, overboughtPrice Change Pct: $2.00 - $10.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SIRI logo
SIRI
Sirius XM Holdings Inc
7.69B
BYRN logo
BYRN
Byrna Technologies Inc
281.11M
RMR logo
RMR
RMR Group Inc
533.45M
ASX logo
ASX
ASE Technology Holding Co Ltd
43.15B
ORN logo
ORN
Orion Group Holdings Inc
545.05M
MCFT logo
MCFT
Mastercraft Boat Holdings Inc
395.64M

Whales Holding NVST

D
Deerfield Management Company, L.P.
Holding
NVST
+9.36%
3M Return
G
Gates Capital Management, Inc.
Holding
NVST
+3.14%
3M Return
A
Asahi Life Asset Management Co.,Ltd.
Holding
NVST
+0.55%
3M Return
A
Ariel Investments, LLC
Holding
NVST
-3.53%
3M Return
P
Paradice Investment Management Pty Ltd.
Holding
NVST
-3.77%
3M Return
T
Tweedy, Browne Company LLC
Holding
NVST
-3.98%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Envista Holdings Corp (NVST) stock price today?

The current price of NVST is 23.55 USD — it has decreased -0.51

What is Envista Holdings Corp (NVST)'s business?

Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.

What is the price predicton of NVST Stock?

Wall Street analysts forecast NVST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVST is22.22 USD with a low forecast of 18.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Envista Holdings Corp (NVST)'s revenue for the last quarter?

Envista Holdings Corp revenue for the last quarter amounts to 705.50M USD, increased 14.36

What is Envista Holdings Corp (NVST)'s earnings per share (EPS) for the last quarter?

Envista Holdings Corp. EPS for the last quarter amounts to 0.23 USD, increased 130.00

How many employees does Envista Holdings Corp (NVST). have?

Envista Holdings Corp (NVST) has 12000 emplpoyees as of May 31 2026.

What is Envista Holdings Corp (NVST) market cap?

Today NVST has the market capitalization of 3.83B USD.